Biolife Solutions (BLFS) | Financial Analysis & Statements
Biolife Solutions Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
18.8M
Gross Profit
12.0M
63.76%
Operating Income
1.3M
7.17%
Net Income
11.1M
58.93%
EPS (Diluted)
$0.22
Balance Sheet Metrics
Total Assets
405.9M
Total Liabilities
34.0M
Shareholders Equity
371.9M
Debt to Equity
0.09
Cash Flow Metrics
Operating Cash Flow
17.3M
Free Cash Flow
-9.6M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Biolife Solutions Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 96.2M | 82.3M | 143.3M | 161.8M | 119.2M |
| Cost of Goods Sold | 34.1M | 28.6M | 96.5M | 107.9M | 82.1M |
| Gross Profit | 62.1M | 53.7M | 46.8M | 53.8M | 37.0M |
| Gross Margin % | 64.6% | 65.3% | 32.6% | 33.3% | 31.1% |
| Operating Expenses | |||||
| Research & Development | 23.1M | 7.9M | 18.8M | 14.8M | 11.8M |
| Selling, General & Administrative | 55.4M | 50.2M | 80.3M | 69.2M | 47.7M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 78.5M | 58.1M | 99.1M | 84.0M | 59.5M |
| Operating Income | -16.6M | -7.1M | -57.5M | -39.9M | -30.6M |
| Operating Margin % | -17.3% | -8.7% | -40.2% | -24.7% | -25.7% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | 1.8M | -3.6M | -6.9M | -104.2M | 2.1M |
| Pre-tax Income | -12.1M | -11.4M | -66.3M | -144.8M | -29.0M |
| Income Tax | 49.0K | -38.0K | 169.0K | -5.0M | -20.1M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -4.6M | -20.2M | -66.4M | -139.8M | -8.9M |
| Net Margin % | -4.8% | -24.5% | -46.4% | -86.4% | -7.5% |
| Key Metrics | |||||
| EBITDA | -11.9M | 5.6M | -37.1M | 81.5M | -19.6M |
| EPS (Basic) | - | $-0.44 | $-1.52 | $-3.29 | $-0.22 |
| EPS (Diluted) | - | $-0.44 | $-1.52 | $-3.29 | $-0.22 |
| Basic Shares Outstanding | - | 46067073 | 43719185 | 42481027 | 38503944 |
| Diluted Shares Outstanding | - | 46067073 | 43719185 | 42481027 | 38503944 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Biolife Solutions Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 33.0M | 95.4M | 35.4M | 19.4M | 69.9M |
| Short-term Investments | 55.9M | 9.2M | 16.3M | 43.3M | 0 |
| Accounts Receivable | 8.0M | 9.2M | 18.7M | 33.9M | 23.2M |
| Inventory | 30.2M | 29.0M | 43.5M | 34.9M | 28.3M |
| Other Current Assets | 9.5M | 6.0M | 6.8M | 6.9M | 4.7M |
| Total Current Assets | 136.6M | 148.8M | 120.6M | 138.5M | 126.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 12.1M | 14.7M | 31.4M | 36.1M | 35.8M |
| Goodwill | 421.4M | 434.2M | 470.6M | 481.6M | 601.6M |
| Intangible Assets | 4.3M | 9.6M | 21.1M | 32.1M | 152.1M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 3.0M | 6.5M | 7.7M | 9.1M | 9.8M |
| Total Non-Current Assets | 269.3M | 250.7M | 292.1M | 311.8M | 428.2M |
| Total Assets | 405.9M | 399.5M | 412.7M | 450.2M | 554.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.5M | 3.6M | 6.9M | 15.4M | 14.9M |
| Short-term Debt | 7.2M | 12.5M | 10.0M | 4.8M | 3.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | 2.2M | 5.1M |
| Total Current Liabilities | 23.0M | 32.7M | 42.2M | 44.6M | 42.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 10.7M | 17.7M | 32.7M | 38.9M | 23.1M |
| Deferred Tax Liabilities | 189.0K | 124.0K | 188.0K | 250.0K | 5.5M |
| Other Non-Current Liabilities | 171.0K | - | - | 2.3M | 4.9M |
| Total Non-Current Liabilities | 11.0M | 17.8M | 32.9M | 41.5M | 33.5M |
| Total Liabilities | 34.0M | 50.6M | 75.1M | 86.0M | 76.2M |
| Equity | |||||
| Common Stock | 48.0K | 47.0K | 45.0K | 43.0K | 42.0K |
| Retained Earnings | -339.7M | -335.1M | -313.3M | -246.9M | -107.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 371.9M | 348.9M | 337.7M | 364.2M | 478.0M |
| Key Metrics | |||||
| Total Debt | 17.9M | 30.2M | 42.7M | 43.7M | 26.9M |
| Working Capital | 113.6M | 116.0M | 78.4M | 93.9M | 83.4M |
Balance Sheet Composition
Biolife Solutions Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -4.6M | -20.2M | -66.4M | -139.8M | -8.9M |
| Depreciation & Amortization | 4.7M | 8.7M | 12.3M | 16.5M | 12.9M |
| Stock-Based Compensation | 23.0M | 30.9M | 31.7M | 25.3M | 14.0M |
| Working Capital Changes | -2.8M | -2.9M | -2.0M | -18.2M | -2.4M |
| Operating Cash Flow | 37.7M | 16.9M | -31.4M | -122.6M | -5.7M |
| Investing Activities | |||||
| Capital Expenditures | -9.5M | -3.2M | -6.4M | -10.4M | -8.4M |
| Acquisitions | 23.5M | 60.4M | 0 | 0 | 1.6M |
| Investment Purchases | -116.1M | -18.4M | -27.1M | -53.1M | 0 |
| Investment Sales | 41.6M | 21.9M | 56.2M | 8.9M | 0 |
| Investing Cash Flow | -61.3M | 58.6M | 17.8M | -58.1M | -13.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 0 | 0 | 20.0M | 1.6M |
| Debt Repayment | -10.0M | -6.6M | -498.0K | -2.2M | -31.8M |
| Financing Cash Flow | -10.9M | -7.0M | 10.1M | 16.0M | -35.7M |
| Free Cash Flow | 416.0K | 4.9M | -18.9M | -18.9M | -13.0M |
| Net Change in Cash | -34.5M | 68.5M | -3.5M | -164.7M | -54.6M |
Cash Flow Trend
Biolife Solutions Key Financial Ratios
Valuation Ratios
Forward P/E
73.72
Price to Book
2.77
Price to Sales
10.73
PEG Ratio
73.72
Profitability Ratios
Profit Margin
-4.78%
Operating Margin
-0.32%
Return on Equity
-3.37%
Return on Assets
-0.17%
Financial Health
Current Ratio
5.94
Debt to Equity
4.81
Beta
2.00
Per Share Data
EPS (TTM)
$-0.25
Book Value per Share
$7.72
Revenue per Share
$2.02
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BLFS | 1.0B | - | 2.77 | -3.37% | -4.78% | 4.81 |
| Intuitive Surgical | 170.1B | 54.97 | 8.99 | 16.69% | 28.38% | 0.95 |
| Becton, Dickinson | 56.1B | 25.40 | 1.75 | 6.96% | 8.01% | 77.28 |
| Pulse Biosciences | 1.6B | - | 20.17 | -74.45% | -54.00% | 9.34 |
| AtriCure | 1.4B | -117.54 | 2.77 | -2.40% | -2.14% | 15.54 |
| Staar Surgical | 1.2B | 49.73 | 3.58 | -21.70% | -33.60% | 11.14 |
Financial data is updated regularly. All figures are in the company's reporting currency.






